BioSpace News Archive

Nucleome Therapeutics Limited, a biotechnology company decoding the dark matter of the human genome to discover first-in-class precision medicines, announces it has closed an oversubscribed £37.5 million Series A financing round.

Hemispherian AS, a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, is delighted to announce a successful European Innovation Council Accelerator grant application.

Biovica International Biovica announces that the company has submitted its CLIA lab application, marking yet another significant milestone for the US commercial launch of the recent FDA cleared test DiviTum®TKa.

Sirnaomics Ltd. announced that it will present the latest developments on GalAhead™, a GalNAc-RNAi therapeutic platform, and its pipeline programs, at two industry conferences in Boston: the RNA Leaders USA Congress and 18th Drug Discovery Innovation Programme.

Immunovia AB announced changes to its executive management team to accelerate the execution of its strategic priorities.

Mentice AB announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson.

Alvotech and the JAMP Pharma Group announced that the companies have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech, by adding two biosimilar candidates from Alvotech’s pipeline: AVT16 a biosimilar for an immunology product and AVT33, a biosimilar for an oncology product.

BioVie Inc. announced that the Company’s Phase 2 trial assessing NE3107’s potential pro-motoric impact in Parkinson’s disease has fully enrolled 44 patients.

Jazz Pharmaceuticals plc and Zymeworks Inc. announced that Jazz and Zymeworks’ subsidiary, Zymeworks BC Inc., have entered into an exclusive licensing agreement under which Jazz will acquire development and commercialization rights to Zymeworks’ zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia/Pacific territories previously licensed by Zymeworks.

Inversago Pharma Inc. announced the appointment of two new board members: Ed Mathers, BSc, General Partner at New Enterprise Associates and Nanna Lüneborg, PhD, MBA, General Partner at Forbion.